SCHEMBL8987299

SCHEMBL8987299

COc1cccc(C=CC(=O)c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 1.00
MAOB P27338 4/20 0.83
CYP1B1 Q16678 4/20 0.77
CYP1A1 P04798 3/20 0.77
CYP1A2 P05177 3/20 0.77
CYP2D6 P10635 2/20 0.77
ABCG2 Q9UNQ0 2/20 0.73
CYP3A4 P08684 2/20 0.71
ALDH1A1 P00352 2/20 0.70
MAPT P10636 2/20 0.70
MEN1 O00255 1/20 0.70
HSPD1 P10809 1/20 0.70
TNFRSF1A P19438 1/20 0.70
HSPE1 P61604 1/20 0.70
KMT2A Q03164 1/20 0.70
NFKB1 P19838 1/20 0.70
NFKB2 Q00653 1/20 0.70
RELA Q04206 1/20 0.70
MAOA P21397 1/20 0.68
LMNA P02545 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8987297 1.00 BCHE (1.00) BCHEMAOBCYP1B1CYP1A1CYP1A2
SCHEMBL31298986 0.92 MAOB (0.86) BCHEMAOBCYP1B1CYP1A1CYP1A2
SCHEMBL21002197 0.92 MAOB (0.86) BCHEMAOBCYP1B1CYP1A1CYP1A2
SCHEMBL28670848 0.91 MAOB (0.84) BCHEMAOBCYP1B1CYP1A1CYP1A2
SCHEMBL28670846 0.91 MAOB (0.84) BCHEMAOBCYP1B1CYP1A1CYP1A2
SCHEMBL8987072 0.91 MAOB (1.00) BCHEMAOBCYP1B1CYP1A1CYP1A2
SCHEMBL8987069 0.91 MAOB (1.00) BCHEMAOBCYP1B1CYP1A1CYP1A2
SCHEMBL11343789 0.91 MAOB (1.00) BCHEMAOBCYP1B1CYP1A1CYP1A2
SCHEMBL1180395 0.91 MAOB (1.00) BCHEMAOBCYP1B1CYP1A1CYP1A2
SCHEMBL25219562 0.88 MAOB (0.84) BCHEMAOBCYP1B1CYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504491-A Efficient preparation method and application of optically pure beta-cyano ketone 哈尔滨理工大学 2025-02-25 CN claimed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
CN-119504491-A Efficient preparation method and application of optically pure beta-cyano ketone 哈尔滨理工大学 2025-02-25 CN disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
CN-116284114-A Method for synthesizing chiral 1, 3-phosphine alcohol 陕西师范大学 2023-06-23 CN disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
CN-111925324-B Synthetic method of 3-acyl quinoline compound 南通大学 2022-07-29 CN disclosed
EP-3553097-B1 COPOLYMER AND OPTICAL FILM USING SAME TOSOH CORP (JP) 2022-05-04 EP disclosed
CN-108084117-B Method for preparing epoxide by visible light induction 大连理工大学 2020-06-16 CN disclosed
US-20200095358-A1 COPOLYMER AND OPTICAL FILM USING SAME TOSOH CORPORATION (JP) 2020-03-26 US disclosed
EP-3553097-A1 COPOLYMER AND OPTICAL FILM USING SAME Tosoh Corporation (JP) 2019-10-16 EP disclosed
US-9085520-B2 Composition for treating diabetes and metabolic diseases and a preparation method thereof KAOHSIUNG MEDICAL UNIVERSITY (TW) 2015-07-21 US disclosed
US-20140350304-A1 COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF KAOHSIUNG MEDICAL UNIVERSITY (TW) 2014-11-27 US disclosed
WO-2013022951-A1 COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-02-14 WO disclosed
US-5492915-A ANTIINFLAMMATORY AGENTS RHONE-POULENC RORER S.A. (FR) 1996-02-20 US disclosed
US-5366982-A Antiinflammatory agents or antihistamines RHONE-POULENC RORER S.A. (FR) 1994-11-22 US disclosed
EP-0540604-A1 SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS Aventis Pharma S.A. (FR) 1993-05-12 EP disclosed
WO-1992001675-A2 SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS RHONE-POULENC RORER S.A. (FR) 1992-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B BCHE 588/4885MAOB 1004/4885CYP1B1 230/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 BCHE 465/4885MAOB 2435/4885CYP1B1 1027/4885
US-20140350304-A1 COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF FABP1, GYS2, CYP7B1 BCHE 703/4885MAOB 3332/4885CYP1B1 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.